Medulloblastoma is a type of malignant tumor arising in the cerebellum. The clinical importance of programmed cell death 1 ligand–1 (PD-L1) expression in medulloblastoma remains unknown. The aim of the present study was to examine the expression of PD-L1 and tumor-infiltrating T cells, and to evaluate their relationships to the prognosis of patients with medulloblastoma.
The authors immunohistochemically analyzed PD-L1 expression and CD3+ and CD8+ lymphocyte infiltrations in tumor specimens from 16 patients with medulloblastoma.
High expression of PD-L1 was observed in 9 (56.3%) of 16 samples studied. High expression of PD-L1 was associated with low infiltrations of CD3+ or CD8+ lymphocytes. Patients with high expression of PD-L1 had shorter progression-free survival and overall survival times than those with low expression (p = 0.076 and p = 0.099, respectively). In addition, patients with high expression of PD-L1 and with low infiltration of CD8+ lymphocytes had a significantly worse outcome, with a 5-year survival rate of 15%, as compared with the other patients, who had a 5-year survival rate of nearly 90% (p = 0.0048 for progression-free survival and p = 0.010 for overall survival).
These findings indicate that PD-L1 expression was associated with a reduced infiltration of CD8+ T cells and poor prognosis in human medulloblastoma.
HamanishiJMandaiMIwasakiMOkazakiTTanakaYYamaguchiK: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A104:3360–33652007
HamanishiJ, MandaiM, IwasakiM, OkazakiT, TanakaY, YamaguchiK, : Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. 104:3360–3365, 200710.1073/pnas.061153310417360651)| false
KlugerHMZitoCRBarrMLBaineMKChiangVLSznolM: Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res21:3052–30602015
OkazakiT, ChikumaS, IwaiY, FagarasanS, HonjoT: A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. 14:1212–1218, 20132424016010.1038/ni.2762)| false
ParsaAT, WaldronJS, PannerA, CraneCA, ParneyIF, BarryJJ, : Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. 13:84–88, 200710.1038/nm151717159987)| false
PhamCDFloresCYangCPinheiroEMYearleyJHSayourE: Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma. Clin Cancer Res22:582–5952016
SchalperKA, VelchetiV, CarvajalD, WimberlyH, BrownJ, PusztaiL, : In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. 20:2773–2782, 20142464756910.1158/1078-0432.CCR-13-2702)| false
VargheseF, BukhariAB, MalhotraR, DeA: IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. 9:e96801, 201410.1371/journal.pone.009680124802416)| false
WangA, WangHY, LiuY, ZhaoMC, ZhangHJ, LuZY, : The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. 41:450–456, 201510.1016/j.ejso.2015.01.02025682184)| false
WeberJSD’AngeloSPMinorDHodiFSGutzmerRNeynsB: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol16:375–3842015